Adipotide (FTPP - Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic designed to induce targeted fat loss by selectively destroying the blood supply to white adipose tissue. Developed at MD Anderson Cancer Center and the University of Texas, it represents a fundamentally different approach to obesity treatment — rather than suppressing appetite or blocking fat absorption, it physically eliminates fat tissue by cutting off its blood supply. In a landmark 2012 study in obese rhesus monkeys, Adipotide treatment led to 11% body weight loss and 39% reduction in abdominal fat over 4 weeks, with improved insulin resistance. However, reversible kidney toxicity was observed, and the compound has not progressed to human trials.
Key Data
Mechanism of Action
Adipotide contains a targeting sequence (CKGGRAKDC) that binds prohibitin on the surface of blood vessels in adipose tissue, fused to a pro-apoptotic peptide (D(KLAKLAK)2) that disrupts mitochondrial membranes, causing vascular endothelial cell death and subsequent fat tissue resorption.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.